Logo image of SRPT

SAREPTA THERAPEUTICS INC (SRPT) Stock Fundamental Analysis

NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD

46.75  -16.91 (-26.56%)

After market: 37.0999 -9.65 (-20.64%)

Fundamental Rating

5

SRPT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. While SRPT is still in line with the averages on profitability rating, there are concerns on its financial health. SRPT is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

SRPT had positive earnings in the past year.
SRPT had a negative operating cash flow in the past year.
SRPT had negative earnings in 4 of the past 5 years.
SRPT had negative operating cash flow in 4 of the past 5 years.
SRPT Yearly Net Income VS EBIT VS OCF VS FCFSRPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

The Return On Assets of SRPT (5.94%) is better than 93.96% of its industry peers.
The Return On Equity of SRPT (15.40%) is better than 95.56% of its industry peers.
SRPT has a better Return On Invested Capital (6.09%) than 94.14% of its industry peers.
Industry RankSector Rank
ROA 5.94%
ROE 15.4%
ROIC 6.09%
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
SRPT Yearly ROA, ROE, ROICSRPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

SRPT has a better Profit Margin (12.37%) than 95.03% of its industry peers.
SRPT has a better Operating Margin (11.47%) than 94.14% of its industry peers.
With an excellent Gross Margin value of 83.22%, SRPT belongs to the best of the industry, outperforming 85.79% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 11.47%
PM (TTM) 12.37%
GM 83.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
SRPT Yearly Profit, Operating, Gross MarginsSRPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SRPT has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SRPT has more shares outstanding
Compared to 5 years ago, SRPT has more shares outstanding
Compared to 1 year ago, SRPT has an improved debt to assets ratio.
SRPT Yearly Shares OutstandingSRPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SRPT Yearly Total Debt VS Total AssetsSRPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

SRPT has an Altman-Z score of 1.42. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
SRPT's Altman-Z score of 1.42 is fine compared to the rest of the industry. SRPT outperforms 69.80% of its industry peers.
SRPT has a Debt/Equity ratio of 0.74. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.74, SRPT is doing worse than 76.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z 1.42
ROIC/WACC0.65
WACC9.36%
SRPT Yearly LT Debt VS Equity VS FCFSRPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B 1.5B

2.3 Liquidity

A Current Ratio of 4.20 indicates that SRPT has no problem at all paying its short term obligations.
SRPT's Current ratio of 4.20 is in line compared to the rest of the industry. SRPT outperforms 48.67% of its industry peers.
SRPT has a Quick Ratio of 3.18. This indicates that SRPT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SRPT (3.18) is worse than 60.75% of its industry peers.
Industry RankSector Rank
Current Ratio 4.2
Quick Ratio 3.18
SRPT Yearly Current Assets VS Current LiabilitesSRPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

More info and screens

7

3. Growth

3.1 Past

SRPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 137.25%, which is quite impressive.
SRPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 52.98%.
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)137.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%219.15%
Revenue 1Y (TTM)52.98%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%65.94%

3.2 Future

SRPT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 45.47% yearly.
The Revenue is expected to grow by 15.26% on average over the next years. This is quite good.
EPS Next Y214.63%
EPS Next 2Y135.85%
EPS Next 3Y87.02%
EPS Next 5Y45.47%
Revenue Next Year63.91%
Revenue Next 2Y41.64%
Revenue Next 3Y29.45%
Revenue Next 5Y15.26%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SRPT Yearly Revenue VS EstimatesSRPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B
SRPT Yearly EPS VS EstimatesSRPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 15

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 20.50 indicates a rather expensive valuation of SRPT.
Compared to the rest of the industry, the Price/Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 95.03% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.29, SRPT is valued at the same level.
Based on the Price/Forward Earnings ratio of 6.52, the valuation of SRPT can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRPT indicates a rather cheap valuation: SRPT is cheaper than 97.34% of the companies listed in the same industry.
SRPT's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 20.42.
Industry RankSector Rank
PE 20.5
Fwd PE 6.52
SRPT Price Earnings VS Forward Price EarningsSRPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

SRPT's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SRPT is cheaper than 94.85% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.62
SRPT Per share dataSRPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SRPT's earnings are expected to grow with 87.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.1
PEG (5Y)N/A
EPS Next 2Y135.85%
EPS Next 3Y87.02%

More info and screens

0

5. Dividend

5.1 Amount

SRPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SAREPTA THERAPEUTICS INC

NASDAQ:SRPT (5/6/2025, 8:00:00 PM)

After market: 37.0999 -9.65 (-20.64%)

46.75

-16.91 (-26.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26 2025-02-26/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners101.88%
Inst Owner Change-2.58%
Ins Owners4.36%
Ins Owner Change2.44%
Market Cap4.59B
Analysts83.23
Price Target154.99 (231.53%)
Short Float %7.22%
Short Ratio2.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)163.14%
Min EPS beat(2)-22.48%
Max EPS beat(2)348.76%
EPS beat(4)3
Avg EPS beat(4)521.38%
Min EPS beat(4)-22.48%
Max EPS beat(4)1173.24%
EPS beat(8)6
Avg EPS beat(8)617.29%
EPS beat(12)8
Avg EPS beat(12)394.49%
EPS beat(16)9
Avg EPS beat(16)294.13%
Revenue beat(2)2
Avg Revenue beat(2)7.38%
Min Revenue beat(2)2.86%
Max Revenue beat(2)11.9%
Revenue beat(4)3
Avg Revenue beat(4)3.24%
Min Revenue beat(4)-9.09%
Max Revenue beat(4)11.9%
Revenue beat(8)6
Avg Revenue beat(8)3.63%
Revenue beat(12)9
Avg Revenue beat(12)2.59%
Revenue beat(16)11
Avg Revenue beat(16)2.32%
PT rev (1m)-14.7%
PT rev (3m)-17.5%
EPS NQ rev (1m)-206.4%
EPS NQ rev (3m)-175.53%
EPS NY rev (1m)-18.87%
EPS NY rev (3m)-37%
Revenue NQ rev (1m)-1.2%
Revenue NQ rev (3m)-1.19%
Revenue NY rev (1m)-2.83%
Revenue NY rev (3m)-2.67%
Valuation
Industry RankSector Rank
PE 20.5
Fwd PE 6.52
P/S 2.42
P/FCF N/A
P/OCF N/A
P/B 3.01
P/tB 3.06
EV/EBITDA 22.62
EPS(TTM)2.28
EY4.88%
EPS(NY)7.17
Fwd EY15.34%
FCF(TTM)-3.59
FCFYN/A
OCF(TTM)-2.09
OCFYN/A
SpS19.36
BVpS15.55
TBVpS15.27
PEG (NY)0.1
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.94%
ROE 15.4%
ROCE 6.75%
ROIC 6.09%
ROICexc 10.48%
ROICexgc 10.64%
OM 11.47%
PM (TTM) 12.37%
GM 83.22%
FCFM N/A
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score5
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA 4.45
Cap/Depr 389.56%
Cap/Sales 7.73%
Interest Coverage 13.75
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.2
Quick Ratio 3.18
Altman-Z 1.42
F-Score5
WACC9.36%
ROIC/WACC0.65
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)137.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%219.15%
EPS Next Y214.63%
EPS Next 2Y135.85%
EPS Next 3Y87.02%
EPS Next 5Y45.47%
Revenue 1Y (TTM)52.98%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%65.94%
Revenue Next Year63.91%
Revenue Next 2Y41.64%
Revenue Next 3Y29.45%
Revenue Next 5Y15.26%
EBIT growth 1Y181.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year315.82%
EBIT Next 3Y126%
EBIT Next 5Y45.96%
FCF growth 1Y40.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.92%
OCF growth 3YN/A
OCF growth 5YN/A